The United States Patent and Trademark Office (USPTO) has issued patent US12582598B2 to QURIENT CO., LTD. This patent specifically covers a topical anti-inflammatory pharmaceutical composition that includes Zileuton. The claims also extend to the uses of this composition and methods for its preparation.

This patent grant signifies a new intellectual property right for the assignee, potentially impacting market exclusivity for related therapeutic products. While not a regulatory rule imposing obligations on other entities, it is a key development in the pharmaceutical sector that compliance officers overseeing drug development and intellectual property should note. No immediate compliance actions are required for other entities based solely on this patent grant.